Last reviewed · How we verify
BT061
BT061 is a monoclonal antibody targeting CD19.
BT061 is a monoclonal antibody targeting CD19. Used for Relapsed or refractory B-cell non-Hodgkin lymphoma.
At a glance
| Generic name | BT061 |
|---|---|
| Also known as | immune-modulatory antibody BT061, SC or IV administration of BT061 or placebo |
| Sponsor | Biotest |
| Drug class | Monoclonal antibody |
| Target | CD19 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
It works by binding to CD19 on the surface of B cells, marking them for destruction by the immune system. This can help to reduce the number of cancer cells in the body.
Approved indications
- Relapsed or refractory B-cell non-Hodgkin lymphoma
Common side effects
- Infusion-related reactions
- Fatigue
- Nausea
Key clinical trials
- Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis (PHASE2)
- Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX) (PHASE2)
- Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BT061 CI brief — competitive landscape report
- BT061 updates RSS · CI watch RSS
- Biotest portfolio CI